The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis.

Suppr

超能文献

作者信息

Carucci J A, Washenik K, Weinstein A, Shupack J, Cohen D E

机构信息

New York University Medical Center, NY, USA.

出版信息

Arch Dermatol. 1998 Jul;134(7):785-6. doi: 10.1001/archderm.134.7.785.

DOI:10.1001/archderm.134.7.785

PMID:9681340

Abstract

摘要

相似文献

The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis.

Arch Dermatol. 1998 Jul;134(7):785-6. doi: 10.1001/archderm.134.7.785.

Treatment of atopic dermatitis with zafirlukast.

Dermatol Online J. 1999 Nov;5(2):10.

Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma.扎鲁司特：首个被批准用于治疗哮喘的白三烯受体拮抗剂。

Ann Pharmacother. 1997 Sep;31(9):1012-21. doi: 10.1177/106002809703100912.

Zafirlukast for asthma.

Med Lett Drugs Ther. 1996 Dec 20;38(990):111-2.

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.扎鲁司特治疗症状性轻至中度哮喘：一项为期13周的多中心研究。扎鲁司特试验者小组。

Clin Ther. 1997 Jul-Aug;19(4):675-90. doi: 10.1016/s0149-2918(97)80092-6.

Treatment of canine atopic dermatitis with zafirlukast, a leukotriene-receptor antagonist: a single-blinded, placebo-controlled study.用白三烯受体拮抗剂扎鲁司特治疗犬异位性皮炎：一项单盲、安慰剂对照研究。

Can Vet J. 2002 Mar;43(3):203-6.

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.白三烯受体拮抗剂扎鲁司特治疗轻至中度哮喘的疗效。一项随机、双盲、安慰剂对照试验。

Ann Intern Med. 1997 Feb 1;126(3):177-83. doi: 10.7326/0003-4819-126-3-199702010-00001.

Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma.

J Fam Pract. 1999 Jun;48(6):425-32.

Summary of clinical trials with zafirlukast.扎鲁司特临床试验总结。

Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 2):S238-45; discussion S245-8.

Management of asthma with zafirlukast. Clinical experience and tolerability profile.扎鲁司特治疗哮喘。临床经验与耐受性概况。

Drugs. 1996;52 Suppl 6:36-46. doi: 10.2165/00003495-199600526-00007.

引用本文的文献

Leukotriene Receptor Antagonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis.白三烯受体拮抗剂治疗特应性皮炎的系统评价和荟萃分析

Acta Derm Venereol. 2025 May 19;105:adv43140. doi: 10.2340/actadv.v105.43140.

Leukotriene Antagonists in Dermatology.皮肤科中的白三烯拮抗剂

Indian J Dermatol. 2021 Sep-Oct;66(5):575. doi: 10.4103/ijd.IJD_557_18.

Cysteinyl leukotriene E activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D and epithelial cytokines.半胱氨酰白三烯E激活人类2型固有淋巴细胞并增强前列腺素D和上皮细胞因子的作用。

J Allergy Clin Immunol. 2017 Oct;140(4):1090-1100.e11. doi: 10.1016/j.jaci.2016.12.958. Epub 2017 Jan 20.

The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field.在变态反应学领域的皮肤疾病中使用白三烯拮抗剂。

Mediators Inflamm. 2010;2010. doi: 10.1155/2010/628171. Epub 2010 Sep 22.

Emerging treatment of atopic dermatitis.特应性皮炎的新兴治疗方法。

Clin Rev Allergy Immunol. 2007 Dec;33(3):199-203. doi: 10.1007/s12016-007-0043-6.

Leukotriene synthesis inhibitors versus antagonists: the pros and cons.白三烯合成抑制剂与拮抗剂：利弊分析

Curr Allergy Asthma Rep. 2007 May;7(2):126-33. doi: 10.1007/s11882-007-0010-6.

Recent advances in treatment strategies for atopic dermatitis.特应性皮炎治疗策略的最新进展

Drugs. 2004;64(23):2639-66. doi: 10.2165/00003495-200464230-00003.

Childhood atopic eczema.儿童特应性皮炎。

BMJ. 2002 Jun 8;324(7350):1376-9. doi: 10.1136/bmj.324.7350.1376.

Can Vet J. 2002 Mar;43(3):203-6.

Leukotriene receptor antagonist therapy.白三烯受体拮抗剂疗法

Postgrad Med J. 2000 Dec;76(902):767-73. doi: 10.1136/pmj.76.902.767.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验